Texas man claims he developed female breast tissue as a result of Risperdal, Invega use

A new Risperdal mass tort claim has surfaced at the Philadelphia Court of

Common Pleas, this one filed by an out-of-state plaintiff who claims he developed a condition that causes the growth of female breast tissue in males as a result of his use of the pharmaceutical.

Philadelphia attorneys Stephen A. Sheller and Brian J. McCormick, Jr., filed suit Sept. 20 in Philadelphia County Court on behalf of Isaac Garza, a Texas man who says Risperdal use caused him to develop a condition known as gynecomastia.

Garza, whose age is not listed in the complaint, also claims he experienced weight gain, pre-diabetes and sustained emotional and psychological injuries as a result of his use of Risperdal, which is an anti-psychotic medication used to treat schizophrenia and bipolar disorder.

The lawsuit, which was filed as a short-form complaint in the master Risperdal Litigation at Common Pleas Court, states that Garza used Risperdal and/or Risperdal Consta from about 2007 through 2011, and then used Invega and/or Invega Sustenna from 2011 to the present.

The latter two drugs are similarly used to treat certain psychiatric disorders.

The defendants named in the complaint – Janssen Pharmaceuticals, Johnson & Johnson Co., Excerpta Medica Inc. and Elsevier Inc. – are accused of negligence, fraud, strict product liability, breach of implied and express warranties, conspiracy, and of violating Pennsylvania’s Unfair Trade Practices and Consumer Protection Law.

The plaintiff seeks an unspecified amount of compensatory and punitive damages.

 

The case ID number is 130902319.